{"id":"https://openalex.org/W2007709024","doi":"https://doi.org/10.1007/bf00176974","title":"Differences in N-acetylation of the experimental antitumor agent batracylin in the mouse and the rat","display_name":"Differences in N-acetylation of the experimental antitumor agent batracylin in the mouse and the rat","publication_year":1991,"publication_date":"1991-08-01","ids":{"openalex":"https://openalex.org/W2007709024","doi":"https://doi.org/10.1007/bf00176974","mag":"2007709024","pmid":"https://pubmed.ncbi.nlm.nih.gov/1783521"},"language":"en","primary_location":{"id":"doi:10.1007/bf00176974","doi":"https://doi.org/10.1007/bf00176974","is_oa":false,"landing_page_url":"https://doi.org/10.1007/bf00176974","pdf_url":null,"source":{"id":"https://openalex.org/S6037287","display_name":"Investigational New Drugs","issn_l":"0167-6997","issn":["0167-6997","1573-0646"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Investigational New Drugs","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5066722006","display_name":"Matthew M. Ames","orcid":"https://orcid.org/0000-0003-3652-209X","observed_orcids":["https://orcid.org/0000-0003-3652-209X"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]},{"id":"https://openalex.org/I4390039279","display_name":"Mayo Clinic Comprehensive Cancer Center (Minnesota)","ror":"https://ror.org/012wxv498","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723","https://openalex.org/I4390039279"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Matthew M. Ames","raw_affiliation_strings":["Mayo Clinic and Foundation, Department of Oncology, Rochester, MN 55905","Department of Oncology, Division of Oncology Research, Mayo Clinic and Foundation, Rochester, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mayo Clinic and Foundation, Department of Oncology, Rochester, MN 55905","institution_ids":["https://openalex.org/I1330342723","https://openalex.org/I4390039279"]},{"raw_affiliation_string":"Department of Oncology, Division of Oncology Research, Mayo Clinic and Foundation, Rochester, USA","institution_ids":["https://openalex.org/I1330342723"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011795171","display_name":"Dane A. Mathiesen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dane A. Mathiesen","raw_affiliation_strings":["Department of Oncology, Division of Oncology Research, Mayo Clinic and Foundation, 200 First Street Southwest, 55905, Rochester, MN, USA","Department of Oncology, Division of Oncology Research, Mayo Clinic and Foundation, Rochester, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, Division of Oncology Research, Mayo Clinic and Foundation, 200 First Street Southwest, 55905, Rochester, MN, USA","institution_ids":["https://openalex.org/I1330342723"]},{"raw_affiliation_string":"Department of Oncology, Division of Oncology Research, Mayo Clinic and Foundation, Rochester, USA","institution_ids":["https://openalex.org/I1330342723"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5027416118","display_name":"Joel M. Reid","orcid":"https://orcid.org/0000-0003-2872-3123","observed_orcids":["https://orcid.org/0000-0003-2872-3123"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joel M. Reid","raw_affiliation_strings":["Department of Oncology, Division of Oncology Research, Mayo Clinic and Foundation, 200 First Street Southwest, 55905, Rochester, MN, USA","Department of Oncology, Division of Oncology Research, Mayo Clinic and Foundation, Rochester, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Oncology, Division of Oncology Research, Mayo Clinic and Foundation, 200 First Street Southwest, 55905, Rochester, MN, USA","institution_ids":["https://openalex.org/I1330342723"]},{"raw_affiliation_string":"Department of Oncology, Division of Oncology Research, Mayo Clinic and Foundation, Rochester, USA","institution_ids":["https://openalex.org/I1330342723"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":4690,"currency":"USD","value_usd":4690},"apc_paid":null,"fwci":0.4428,"has_fulltext":false,"cited_by_count":12,"citation_normalized_percentile":{"value":0.58891646,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":96},"biblio":{"volume":"9","issue":"3","first_page":"219","last_page":"225"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.9937000274658203,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.9937000274658203,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12356","display_name":"Bioactive Compounds and Antitumor Agents","score":0.0038999998942017555,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T14072","display_name":"Immunotoxicology and immune responses","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/n-acetylation","display_name":"N-acetylation","score":0.875},{"id":"https://openalex.org/keywords/species-differences","display_name":"species differences","score":0.5979999899864197},{"id":"https://openalex.org/keywords/oral-toxicity","display_name":"oral toxicity","score":0.7639999985694885},{"id":"https://openalex.org/keywords/systemic-exposure","display_name":"systemic exposure","score":0.8450000286102295},{"id":"https://openalex.org/keywords/drug-metabolism","display_name":"drug metabolism","score":0.6840000152587891},{"id":"https://openalex.org/keywords/anticancer-agents","display_name":"anticancer agents","score":0.7049999833106995},{"id":"https://openalex.org/keywords/p388-leukemia","display_name":"P388 leukemia","score":0.7900000214576721}],"concepts":[{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.743450939655304},{"id":"https://openalex.org/C2777056448","wikidata":"https://www.wikidata.org/wiki/Q285166","display_name":"Oral administration","level":2,"score":0.7399380207061768},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6970590353012085},{"id":"https://openalex.org/C25938499","wikidata":"https://www.wikidata.org/wiki/Q7663812","display_name":"Systemic administration","level":3,"score":0.6905729174613953},{"id":"https://openalex.org/C2777477808","wikidata":"https://www.wikidata.org/wiki/Q407595","display_name":"Metabolite","level":2,"score":0.6812833547592163},{"id":"https://openalex.org/C2776093070","wikidata":"https://www.wikidata.org/wiki/Q621636","display_name":"Route of administration","level":2,"score":0.5522444844245911},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.5410756468772888},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5151454210281372},{"id":"https://openalex.org/C2777928079","wikidata":"https://www.wikidata.org/wiki/Q2677027","display_name":"Rat\u00f3n","level":2,"score":0.4590848982334137},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.3441512882709503},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.2563364505767822},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.24724867939949036},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.2357408106327057},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000107","descriptor_name":"Acetylation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":false},{"descriptor_ui":"D007928","descriptor_name":"Lethal Dose 50","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":false},{"descriptor_ui":"D013045","descriptor_name":"Species Specificity","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051381","descriptor_name":"Rats","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1007/bf00176974","doi":"https://doi.org/10.1007/bf00176974","is_oa":false,"landing_page_url":"https://doi.org/10.1007/bf00176974","pdf_url":null,"source":{"id":"https://openalex.org/S6037287","display_name":"Investigational New Drugs","issn_l":"0167-6997","issn":["0167-6997","1573-0646"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Investigational New Drugs","raw_type":"journal-article"},{"id":"pmid:1783521","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/1783521","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Investigational new drugs","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.8209999799728394}],"study_designs":[],"awards":[{"id":"https://openalex.org/G1691499259","display_name":"PRECLINICAL PHARMACOLOGY OF ANTITUMOR AGENTS","funder_award_id":"n01cm067904-000","funder_id":"https://openalex.org/F4320332161","funder_display_name":"National Institutes of Health"},{"id":"https://openalex.org/G3609797743","display_name":null,"funder_award_id":"CM 67904","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"}],"funders":[{"id":"https://openalex.org/F4320306085","display_name":"U.S. Department of Health and Human Services","ror":"https://ror.org/033jnv181"},{"id":"https://openalex.org/F4320321040","display_name":"National Science Council","ror":"https://ror.org/02kv4zf79"},{"id":"https://openalex.org/F4320332161","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88"},{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":6,"referenced_works":["https://openalex.org/W586325336","https://openalex.org/W626666553","https://openalex.org/W1727163805","https://openalex.org/W1976542799","https://openalex.org/W2013331166","https://openalex.org/W2073509461"],"related_works":["https://openalex.org/W2002183411","https://openalex.org/W356927717","https://openalex.org/W1977921226","https://openalex.org/W2160812530","https://openalex.org/W2073509461","https://openalex.org/W306911265","https://openalex.org/W2050448027","https://openalex.org/W1976542799","https://openalex.org/W2048120675","https://openalex.org/W311746081"],"abstract_inverted_index":null,"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2016,"cited_by_count":2},{"year":2014,"cited_by_count":2},{"year":2013,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}